JAMA DermMeta-analysis
Drug Survival of Omalizumab and Factors Associated With Discontinuation in Chronic Urticaria: A Meta-Analysis.
ConclusionThe results of this systematic review and meta-analysis suggest that omalizumab demonstrates long-term drug survival in CU, with discontinuation more often due to disease control than adverse events. Autoimmune comorbidities (mainly thyroid-related) were associated with reduced drug survival, primarily due to lack of efficacy, whereas atopic comorbidities were associated with discontinuation after disease control, underscoring the need for improved endotype-driven treatment strategies.
Altayf A, Kolkhir P, … senior author Elhadi MJAMA Dermatology